Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).

Hepatology (Baltimore, Md.) - 1 Apr 2012

Guedj Jeremie, Dahari Harel, Shudo Emi, Smith Patrick, Perelson Alan S

Abstract excerpt

UNLABELLED: Mericitabine (RG7128) is a nucleoside polymerase inhibitor (NPI), which requires intracellular uptake and phosphorylation to two active triphosphates. Mathematical modeling has provided important insights for characterizing hepatitis C virus (HCV) RNA decline and estimating in vivo effectiveness of antiviral agents; however, it has not been used to characterize viral kinetics with NPIs. HCV RNA was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Deoxycytidine
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Models, Theoretical

Share to Viral Load

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 22095398
DOI: 10.1002/hep.24788
PMCID: PMC3322641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).PMID 22095398Read ↗

Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.Semantic proximity Read ↗

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.Semantic proximity Read ↗

Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA PolymeraseSemantic proximity Read ↗

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.Semantic proximity Read ↗

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.Semantic proximity Read ↗

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.Semantic proximity Read ↗

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.Semantic proximity Read ↗

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.Semantic proximity Read ↗

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeSemantic proximity Read ↗

Triphasic decline of hepatitis C virus RNA during antiviral therapySemantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.